Source: European Medicines Agency
Area: News
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion on a new indication for nepafenac (Nevanac) as follows:
"Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients".
Uncategorized